Assuring access to quality antiretroviral medicines: the WHO Prequalification of Medicines Program and access to HIV treatment

Access to hepatitis C medicines

Hepatitis C is a global epidemic. Worldwide, 185 million people are estimated to be infected, most of whom live in low- and middle-income countries. Recent advances in the development of antiviral drugs have produced therapies that are more effective, safer and better tolerated than existing treatments for the disease. These therapies present an opportunity to curb the epidemic, provided that t...

pharmaceutical strategic purchasing: a key to improve access to medicines

pharmaceuticals are often considered as the most significant cost driver of health care expenditures and at the same time have a major impact on patients’ curative processes and outcomes. other pieces of evidence emphasize that drugs are the input for the production of good health. they are considered as the most important and expensive element in the healthy supply chain and are more associate...

Access to medicines - overcoming the barriers.

Access to medicines versus access to treatment: the case of type 1 diabetes.

a International Insulin Foundation, London, England. b Judge Business School, University of Cambridge, Cambridge, England. Correspondence to Ariane McCabe (e-mail: [email protected]). doi:10.2471/BLT.07.048710 (Submitted: 10 November 2007 – Revised version received: 22 March 2008 – Accepted: 16 April 2008 ) Introduction In recent years considerable attention has been paid to the issue of access t...

Regulatory framework for access to safe, effective quality medicines.

Medicines of uncertain quality, safety and efficacy can be worse than no treatment at all. It is the responsibility of national medicines regulatory authorities to protect patients from harm. Yet, there are great disparities in regulatory capacity globally, preventing large populations from accessing the benefits of advances in the pharmaceutical field. This article describes the main regulator...